Anne Marit de Groot

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

Jerald Sadoff, Mathieu Le Gars, Georgi Shukarev et al. · New England Journal of Medicine · 2021 · 1.2K citations · Full text

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

Galit Alter, Jingyou Yu, Jinyan Liu et al. · Nature · 2021 · 342 citations · Full text

Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19

Kathryn E. Stephenson, Mathieu Le Gars, Jerald Sadoff et al. · JAMA · 2021 · 313 citations · Full text

Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial

Jerald Sadoff, Mathieu Le Gars, Georgi Shukarev et al. · 2020 · 141 citations · Full text

Viral Diagnostics, Immunology, Immunodominance +21

Cathelicidins Inhibit <i>Escherichia coli</i>–Induced TLR2 and TLR4 Activation in a Viability-Dependent Manner

Maarten Coorens, Viktoria A. F. Schneider, Anne Marit de Groot et al. · The Journal of Immunology · 2017 · 93 citations · Full text